Status:
COMPLETED
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Institute of Cancer Research, United Kingdom
Conditions:
Breast Cancer
Eligibility:
FEMALE
Up to 75 years
Phase:
PHASE3
Brief Summary
The purpose of this study was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastroz...
Eligibility Criteria
Inclusion
- Post-menopausal status; age ≤75 years;
- histologically confirmed invasive breast cancer with metastases in the axillary lymph nodes;
- oestrogen receptor status positive or unknown;
- primary treatment (surgery +/- radiotherapy, +/- chemotherapy) completed
Exclusion
- Clinical evidence of metastatic disease (including local or remote recurrence, even if the patient appeared to be in complete remission at the time of randomisation).
Key Trial Info
Start Date :
March 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
448 Patients enrolled
Trial Details
Trial ID
NCT00286117
Start Date
March 1 1998
End Date
May 1 2006
Last Update
May 1 2009
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Arezzo, Italy
2
Research Site
Bologna, Italy
3
Research Site
Casalpusterlengo, Italy
4
Research Site
Catania, Italy